Hospital
Trustees of Mease Hospital INC
Trustees of Mease Hospital INC was paid $2.90M by Medicaid between Jan 2018 and Nov 2024, across 100 billing codes. Its largest line is 99283, emergency room visit (moderate) — 25% of everything it billed.
33Billing provider infoTRUSTEES OF MEASE HOSPITAL INC
DUNEDIN, FL 34698
DUNEDIN, FL 34698
33aNPI1336125640assigned 12/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.90M
24GClaims145,750
24DCodes billed100
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#108 of 163
Median peer was paid$4.77M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,868 | $99K | |
| 2019 | 29,560 | $370K | |
| 2020 | 24,273 | $331K | |
| 2021 | 34,476 | $606K | |
| 2022 | 27,990 | $735K | |
| 2023 | 13,886 | $541K | |
| 2024incomplete | 4,697 | $216K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 9,722 | 8,463 | $734K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 10,305 | 8,508 | $621K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 5,836 | 4,527 | $342K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.8% | 1,737 | 1,452 | $225K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.6% | 2,894 | 2,141 | $162K |
| 80053 | Comprehensive metabolic panel | 5.3% | 6,219 | 4,877 | $152K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3.6% | 2,419 | 1,934 | $104K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 1,297 | 1,178 | $99K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.4% | 4,865 | 3,469 | $99K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 12,272 | 8,367 | $53K |
| G0378 | Hospital observation service, per hour | 1.2% | 3,913 | 1,531 | $35K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 947 | 795 | $30K |
88 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,327 | $25K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,474 | $24K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 111 | $21K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,111 | $20K |
| 81025 | <1% | 2,265 | $20K | |
| 87631 | <1% | 718 | $19K | |
| 80047 | <1% | 1,780 | $10K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,590 | $8K |
| 82948 | <1% | 3,065 | $8K | |
| 81003 | <1% | 6,448 | $8K | |
| 84484 | <1% | 4,115 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 921 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,126 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,883 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,140 | $6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,049 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 922 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,640 | $4K |
| A9270 | Non-covered item or service | <1% | 1,183 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,031 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,892 | $3K |
| 73562 | <1% | 138 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 745 | $2K |
| 83880 | <1% | 1,589 | $1K | |
| 84703 | <1% | 1,317 | $1K | |
| 82330 | <1% | 1,572 | $1K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 457 | $1K |
| 87040 | <1% | 683 | $1K | |
| 83690 | <1% | 2,538 | $1K | |
| 85610 | <1% | 1,282 | $996.51 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 742 | $948.38 |
| 73610 | <1% | 40 | $846.24 | |
| 72100 | <1% | 93 | $801.70 | |
| 81001 | <1% | 322 | $715.10 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 199 | $676.21 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 55 | $665.66 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 288 | $600.44 |
| 87510 | <1% | 591 | $581.08 | |
| 87660 | <1% | 591 | $574.06 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 83 | $570.63 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 401 | $546.60 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 29 | $534.69 |
| 87641 | <1% | 82 | $481.90 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 109 | $481.55 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 50 | $481.55 |
| 84145 | <1% | 195 | $453.38 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 24 | $419.71 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,016 | $347.91 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,052 | $294.35 |
| 73030 | <1% | 30 | $265.02 | |
| 80076 | <1% | 126 | $259.74 | |
| 87480 | <1% | 594 | $199.75 | |
| 85730 | <1% | 78 | $186.86 | |
| 85027 | <1% | 743 | $157.62 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 387 | $156.65 |
| 0353U | <1% | 37 | $150.54 | |
| 80061 | Lipid panel | <1% | 85 | $146.74 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13 | $145.25 |
| 83735 | <1% | 733 | $95.73 | |
| 76830 | Ultrasound, transvaginal | <1% | 27 | $71.05 |
| 87077 | <1% | 356 | $68.79 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 827 | $54.83 |
| 73630 | <1% | 14 | $35.85 | |
| 87640 | <1% | 29 | $8.34 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 23 | $1.43 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 478 | $0.71 |
| 0352U | 0% | 17 | $0.00 | |
| 83605 | 0% | 589 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 179 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 219 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 16 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 26 | $0.00 |
| 85652 | 0% | 13 | $0.00 | |
| 86901 | 0% | 14 | $0.00 | |
| 82077 | 0% | 13 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 51 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 33 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 47 | $0.00 |
| 86140 | 0% | 37 | $0.00 | |
| 82550 | 0% | 17 | $0.00 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 0% | 13 | $0.00 |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 13 | $0.00 |
| 87186 | 0% | 242 | $0.00 | |
| 84702 | 0% | 45 | $0.00 | |
| 86900 | 0% | 14 | $0.00 | |
| 80164 | 0% | 23 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 26 | $0.00 |
| 72125 | Computed tomography, cervical spine; without contrast material | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTREMONTI, CARL (CFO, BAYCARE HOSPITAL DIVISION)
| Provider | Location | Paid |
|---|---|---|
| Trustees of Mease Hospital INC | Clearwater, FL | $9.19M |
| Morton Plant Hospital Association INC | New Port Richey, FL | $7.34M |
| Behavioral Health Management Services, INC. | Tampa, FL | $1.18M |
| Behavioral Health Management Services, INC. | Clearwater, FL | $698K |
| Morton Plant Hospital Association, INC | Belleair, FL | $582.59 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.